2021 World Conference on Lung Cancer

Melissa Johnson (Sarah Cannon Research Institute, Nashville, TN, USA) presented results from a randomised, open-label, phase 3 study of 1013 patients with metastatic, EGFR and ALK wild-type non-small-cell lung cancer (NSCLC) comparing chemotherapy (type chosen on the basis of histology) plus durvalumab (1500 mg daily; n=338) versus chemotherapy plus durvalumab and tremelimumab (75 mg daily; n=338) versus chemotherapy alone (n=337) as first-line treatment. Median progression-free survival (co-primary endpoint) was 5·5 months (95% CI 4·7–6·5) in the durvalumab plus chemotherapy group versus 4·8 months (4·6–5·8) in the chemotherapy alone group (hazard ratio [HR] 0·74; 95% CI 0·62–0·89; p=0·0009) and median overall survival (co-primary endpoint) was 13·3 months (11·4–14·7) versus 11·7 months (10·5–13·1; HR 0·86; 0·72–1·02; p=0·076). Grade 3 or 4 treatment-related adverse events occurred in 149 (45%) patients in the chemotherapy plus durvalumab group, 171 (52%) in the chemotherapy plus durvalumab and tremelimumab group, and 148 (44%) in the chemotherapy alone group.